Table 1.
Clinical characteristics of patients
| Characteristics | Training cohort (n = 64), no. (%) | Test cohort (n = 20), no. (%) | P | Patients with missing or incomplete data (n = 83), no. (%) | ||
|---|---|---|---|---|---|---|
| Scanner 1 (n = 39) | Scanner 2 (n = 29) | Scanner 3 (n = 15) | ||||
| *Gender | 0.690 | |||||
| Male | 45 (70.31) | 15 (75.00) | 28 (71.79) | 21 (72.41) | 10 (66.67) | |
| Female | 19 (29.69) | 5 (25.00) | 11 (28.21) | 8 (27.59) | 5 (33.33) | |
| *Age (years) | 0.861 | |||||
| < 60 | 50 (78.13) | 16 (80.00) | 24 (61.54) | 22 (75.86) | 10 (66.67) | |
| ≥ 60 | 14 (21.87) | 4 (20.00) | 15 (38.46) | 7 (24.14) | 5 (33.33) | |
| *Primary site of tumor | 0.078 | |||||
| Upper aerodigestive tract | 51 (79.69) | 12 (60.00) | 30 (76.92) | 25 (86.21) | 13 (86.67) | |
| Non-upper aerodigestive tract | 13(20.31) | 8 (40.00) | 9 (23.08) | 4 (13.79) | 2 (13.33) | |
| *Ann Arbor stage | 0.182 | |||||
| I–II | 51 (79.69) | 13 (65.00) | 30 (76.92) | 23 (79.31) | 11 (73.33) | |
| III–IV | 13(20.31) | 7 (35.00) | 9 (23.08) | 6 (20.69) | 4 (26.67) | |
| *B symptoms | 0.213 | |||||
| Yes | 25 (39.06) | 9 (45.00) | – | – | – | |
| No | 39 (60.94) | 11 (55.00) | – | – | – | |
| *ECOG score | 0.038 | |||||
| 0 | 36 (56.25) | 6 (30.00) | – | – | – | |
| 1 | 19 (29.69) | 7 (35.00) | – | – | – | |
| 2–5 | 9 (14.06) | 7 (35.00) | – | – | – | |
| *PINK | 0.230 | |||||
| Low risk (0) | 37 (57.81) | 11 (55.00) | – | – | – | |
| Intermediate risk (1) | 16 (25.00) | 1 (5.00) | – | – | – | |
| High risk (2–4) | 11 (17.19) | 8 (40.00) | – | – | – | |
| **18F-FDG uptake (SUVmax) | 13.17 ± 6.90 | 14.48 ± 4.92 | 0.432 | 12.01 ± 6.07 | 16.40 ± 6.78 | 21.23 ± 9.06 |
| **Follow-up period (months) | 33.70 ± 20.82 | 38.70 ± 23.96 | 0.369 | – | – | – |
*P values were calculated using the chi-squared test for categorical variables and nonparametric test for continuous variables
**Mean ± SD; independent sample t test was used to compare differences in quantitative parameters between the groups
Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; PINK, prognostic index of natural killer lymphoma; SUVmax: maximum standardized uptake value